Meta‐analysis: Risk of pancreatic cancer in patients with inflammatory bowel disease
Alimentary Pharmacology & Therapeutics · 2024-04 · 59 (8) · 918-927
DOI: 10.1111/apt.17919 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 19.02.2024. Verfasst von Mohammad Zamani und 5 weiteren Autor:innen. Beteiligte Einrichtung: Digestive Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Crohn Disease, Inflammatory Bowel Diseases, Pancreatic Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Studies exploring the association between inflammatory bowel disease (IBD) and pancreatic cancer have reported inconsistent results.
Aims
To provide a comprehensive overview of the risk of pancreatic cancer development in patients with IBD.
Methods
We searched Embase, PubMed, Scopus and ProQuest from inception to 31 October 2023. We included population‐based cohort studies examining the risk of incident pancreatic cancer in adult patients with IBD compared to the non‐IBD population. We also retrieved Mendelian randomisation (MR) studies investigating the relationship of IBD with pancreatic cancer risk. We conducted random‐effects meta‐analyses and provided pooled relative risks (RRs) with 95% confidence intervals (CIs).
Results
We included 13 studies. Among 11 cohort studies, the risk of developing pancreatic cancer increased by 79% in patients with IBD (RR = 1.79 [95% CI: 1.16–2.75]; I 2 = 95.7%). Patients either with Crohn's disease (RR = 1.42 [95% CI: 1.24–1.63]) or ulcerative colitis (RR = 1.50 [95% CI: 1.17–1.92]) had increased risk ( p for interaction = 0.72). The annual incidence of pancreatic cancer potentially attributable to IBD increased by 55 cases (95% CI: 17–103) per million. Two MR studies demonstrated that genetic liability to IBD was associated with an increased risk of pancreatic cancer.
Conclusions
Our results suggest a moderate increase in the risk of pancreatic cancer in patients with IBD, which may be further heightened by genetic predisposition to IBD. The increased risk of pancreatic cancer is probably similar in Crohn's disease and ulcerative colitis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Digestive Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
- Kern Center for the Science of Healthcare Delivery Research, Mayo Clinic, Rochester, Minnesota, USA.
- Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
- Digestive Oncology Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
- School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia.
ORCID-Profile: Mohammad Zamani, Ashwin N Ananthakrishnan, Reza Malekzadeh, Nicholas J Talley
Zitieren
APA
Zamani, M., Alizadeh-Tabari, S., Murad, M. H., Ananthakrishnan, A. N., Malekzadeh, R., & Talley, N. J. (2024). Meta‐analysis: Risk of pancreatic cancer in patients with inflammatory bowel disease. Alimentary Pharmacology & Therapeutics, 59(8), 918-927. https://doi.org/10.1111/apt.17919
Vancouver
Zamani M, Alizadeh-Tabari S, Murad MH, Ananthakrishnan AN, Malekzadeh R, Talley NJ. Meta‐analysis: Risk of pancreatic cancer in patients with inflammatory bowel disease. Alimentary Pharmacology & Therapeutics. 2024;59(8):918-927. doi:10.1111/apt.17919
BibTeX
@article{Zamani2024,
author = {Zamani, Mohammad and Alizadeh-Tabari, Shaghayegh and Murad, Mohammad Hassan and Ananthakrishnan, Ashwin N and Malekzadeh, Reza and Talley, Nicholas J},
title = {Meta‐analysis: Risk of pancreatic cancer in patients with inflammatory bowel disease},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
volume = {59},
number = {8},
pages = {918--927},
doi = {10.1111/apt.17919}
}
EUVIMED